Jaguar Health, Inc.

For the period ended Mar 31, 2026. Filed May 20, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 20, 2026

JAGX$0.44+0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

	Three Months Ended
	March 31,
(In thousands, except share and per share data) · 2026 · 2025
License revenue	$	19,043	$	43
Product revenue, net		1,204		2,171
Grant revenue		25		—
Total revenue, net		20,272		2,214
Operating expenses
Cost of product revenue		1,158		515
Research and development		3,928		3,730
Sales and marketing		896		2,493
General and administrative		4,108		4,897
Total operating expenses		10,090		11,635
Income (loss) from operations		10,182		(9,421)
Interest income (expense)		(699)		56
Loss on extinguishment of debt		(628)		—
Changes in fair value of freestanding and hybrid financial instruments designated at Fair Value Option		(337)		(1,343)
Other income (expense)		205		112
Income (loss) before income tax expense		8,723		(10,596)
Income tax expense		—		—
Net income (loss)	$	8,723	$	(10,596)
Net loss attributable to noncontrolling interest	$	(126)	$	(132)
Stock dividends to preferred stockholders	$	9,470	$	—
Deemed dividend to preferred stockholders	$	6,063	$	—
Preferred returns to preferred stockholders	$	331	$	—
Net loss attributable to common stockholders	$	(7,015)	$	(10,464)
Net loss per share, basic and diluted	$	(13.60)	$	(584.45)
Weighted-average common stock outstanding, basic and diluted		515,788		17,904

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.